European Companies Search Engine

UK funding (£190,760): Development and Commercialisation of a Second Generation Rapid Diagnostic Test (RDT) for Human African Trypanosomiasis (HAT) and other Kinetoplastida Ukri1 Jan 2016 UK Research and Innovation, United Kingdom

Overview

Text

Development and Commercialisation of a Second Generation Rapid Diagnostic Test (RDT) for Human African Trypanosomiasis (HAT) and other Kinetoplastida

Abstract The overall aim of this research is to complete the further development and commercialisation of new tests for the detection and diagnosis of the parasite Human African Trypanosomiasis (HAT or sleeping sickness), building upon and completing previously funded BBSRC applications. HAT threatens 43.4 million people in the sub-Saharan area of Africa, is the result of infection by parasites transmitted by the tsetse fly, and the development of new, more reliable and economic diagnostic biomarkers and assays is essential, particularly for surveillance and to curb transmission in the remaining moderate to high risk foci. Our approach is also amenable to the development of new diagnostic tests for the diagnosis, monitoring and surveillance of other diseases caused by parasite diseases. We will therefore also apply our technology to the development of new diagnostic tests for other diseases caused by Trypanosomes and Kinetoplastid diseases of commercial and social importance.
Category Research Grant
Reference BB/N012496/1
Status Closed
Funded period start 01/01/2016
Funded period end 25/08/2017
Funded value £190,760.00
Source https://gtr.ukri.org/projects?ref=BB%2FN012496%2F1

Participating Organisations

University of Kent
Mahidol University
Institute of Tropical Medicine Antwerp

The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: University of Kent, Canterbury.